Market Scenario:
Pericarditis is inflammation of the pericardium (the fibrous sac surrounding the heart). Symptoms typically include a sudden onset of sharp chest pain. The pain may also be felt in the shoulders, neck, or back. It generally is better sitting up and worse when lying down or breathing deeply.
The increasing prevalence of cardiovascular diseases such as heart attack & hypertension, favorable reimbursement policies, and increasing preference for minimally invasive procedures are the major drivers propelling market growth. However, the side-effects of anti-inflammatory drugs and the risk of bacterial infections constrain the growth of the market.
The Global Pericarditis Market is expected to register 7.96% CAGR and is anticipated to reach USD 2,741.39 Million by 2023.
Market Dynamics
The prevalence of cardiovascular diseases is found to be increasing over the last decade. This is attributed to the rising incidences of chronic diseases such as obesity and diabetes, which are major risk factors for cardiovascular diseases such as pericarditis, heart attack, and hypertension. As per the American Heart Association, nearly 92.1 million Americans were diagnosed with cardiovascular diseases in 2017. Additionally, it also stated that the prevalence is found to be higher in men than in women. Furthermore, in the same year, more than 92% of the patients exhibited major symptoms of heart diseases such as chest pain, heartburns, and strokes.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1847
Recently, the prevalence of cardiovascular diseases is found to be increasing from the last few years. The American Heart Association stated that in 2015, 3.7% of the Asian population was diagnosed with chronic heart disease, while 21% of the people had hypertension.
Cardiovascular disease is one of the significant chronic disease responsible for a high death toll across the globe. This emphasizes the need for the development of new diagnostics and treatment devices around the world. The market is also affected by the increasing number of people diagnosed with these diseases at an early stage. Therefore, the prevalence of cardiovascular disease would drive the growth of the market during the forecast period.
The market is driven by the increasing number of patients suffering from cardiovascular diseases, thus signifying the need for the development of new technologically advanced devices for monitoring the heart rate. Continuous monitoring of cardiovascular diseases is an important aspect of cardiology. Therefore, the prevalence of pericarditis is increasing with a rise in the prevalence of cardiovascular diseases, fueling market growth.
Segmentation
The global pericarditis market has been segmented into type, application, and end user.
Based on type, the global market has been segmented acute pericarditis, recurrent pericarditis, and chronic pericarditis.
Based on diagnosis & treatment, the global market has been divided into diagnosis and treatment. The diagnosis segment is further divided into electrocardiogram (ECG), echocardiogram, computerized tomography (CT), X-Ray. The treatment segment is bifurcated into medication (non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine) and surgical treatment.
Based on end user, the global market has been segmented into hospitals & clinics and medical institutes & research laboratories. The hospitals & clinics segment accounted for a market value of USD 840.30 million in 2017.
Key Players
The prominent players in the global pericarditis market are Pfizer Inc., AstraZeneca Plc, Novartis International AG, Allergan plc., and Merck & Co., Inc. are the top five market players in this market. Apart from these, Bayer AG, Reckitt Benckiser Group Plc., PerkinElmer, Inc., FUJIFILM Holdings Corporation, Sanofi, and Johnson & Johnson Services, Inc. are some of the other major players in the global market.
Some of the key strategies followed by the players operating in the global pericarditis market are innovation, product development, acquisition, and expansion.
Regional Analysis
The global pericarditis market, based on region, is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is estimated to dominate the global pericarditis market during the forecast period. This is attributed to the rising investments in research and development owing to investments in reputed research centers and government institutions and increasing expenditure on healthcare play a vital role in the growth of the regional market. Besides, several research grants are given by governmental agencies.
The European market for pericarditis is expected to be the second-largest during the forecast period. The presence of medical device companies, the rising burden of rheumatoid arthritis (RA), and growing healthcare spending are expected to boost the growth of the market in this region. Additionally, the companies operating in the market are mainly focusing on mergers and acquisition, which is expected to support market growth.
Asia-Pacific is estimated to be the fastest-growing market due to the growing geriatric population, rapid developments in technology. In addition to this, improving healthcare infrastructure has increased the number of research activities in the region. Moreover, in the region, China accounted for a market share of 24.6% in 2017.
Furthermore, the market in the Middle East & Africa is expected to witness slow growth due to limited access to healthcare facilities.
Key Updates
- In July 2017, Pfizer Inc. extended the collaboration with Catalent, Inc., a global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products for the development and manufacture of Advil Liqui-Gels.
- In October 2018, Reckitt Benckiser (RB) launched a 24-hour pain relief patch along with a campaign to educate patients about pain to encourage patients to facilitate pain management.
- In October 2018, FUJIFILM Medical Systems USA, Inc., a provider of diagnostic imaging and medical informatics solutions launched the FCT Embrace wide bore computed tomography (CT) imaging unit in the US, thereby entering into the US computed tomography market.
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/pericarditis-market-1847
It results in sharp chest pain, which might also extend to the neck, shoulder, or back.
Recent years have witnessed a hike in the number of pericarditis cases.
Market Research Future (MRFR) has added a new report to its portfolio, where it has studied the global pericarditis market thoroughly.
As per the report, the market is likely to reach USD 2,741.39 Mn at a CAGR of 7.96% over the forecast period of 2018-2023.Request Sample Copy:https://www.marketresearchfuture.com/sample_request/7212The development of various new minimally invasive surgeries has prompted patients suffering from pericarditis to opt for diagnosis & treatment.
Besides, increasing availability of hassle-free reimbursement on surgeries has led to an increase in the volume of pericarditis surgeries, which has fueled the growth of the pericarditis market.
The treatment segment has been further segmented into medication and surgical treatment.
The global Drug Discovery Informatics market size is expected to reach USD 12.52 billion by 2028 according to a new study by Polaris Market Research.
The report “Drug Discovery Informatics Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Antibacterial Drugs {Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, Others}, Antiviral Drugs, Antifungal Drugs); By Infection Type; By Regions; Segment Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.Rising tolerance towards antibiotics in lethal pathogens also induced the market demand for novel therapeutics for treating hospital acquired infections.
The majority of players in the market for Drug Discovery Informatics are continuously involved in research & development activities to develop new drugs to gain a competitive advantage.In this direction, in June 2019, Food & Drug Administration (FDA) approved Merck’s Zerbaxa (ceftolozane and tazobactam) drug for the treatment of ventilator-associated infections in patients aged 18 years and older.
This is expected to drive the market for Drug Discovery Informatics.Over the past few decades, chronic diseases such as diabetes, heart-related ailments, and arthritis are rising at an alarming speed.
As per the data published by International Agency for Research on Cancer (IARC), in 2018, reported around 18.1 million new cancer cases.Get Sample PDF @ https://www.polarismarketresearch.com/industry-analysis/drug-discovery-informatics-market/request-for-sampleAsia Pacific is expected to register a lucrative market growth rate over the hospital acquired infection therapeutic study period.
This market growth for hospital acquired infection therapeutic is attributed to the rising prevalence of chronic diseases in developing nations with high disposable income, which had led to an increase in hospital admissions.For instance, as per the market study done by Globocan, in 2018, there were 4,285,033 new cancer cases in China.
The Global Testosterone Replacement Therapy Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2026 gives an evaluation of the market developments based on historical studies and comprehensive research respectively.
The market segments are also provided with an in-depth outlook of the competitive landscape and a listing of the profiled key players.The report offers a value chain analysis that gives a comprehensive outlook of the market.
The attractiveness analysis of this market has also been included so as to evaluate the segments that are anticipated to be profitable during the forecast period.Final Report will cover the impact of COVID-19 on this industry.Browse the complete Global Testosterone Replacement Therapy Market Research Report – Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2026 @ https://www.decisiondatabases.com/ip/8960-testosterone-replacement-therapy-market-reportThe report also covers the complete competitive landscape of the global Testosterone Replacement Therapy market with company profiles of key players such as:AbbVie, Inc.Allergan plcBayer AGEndo Pharmaceuticals, Inc.Eli Lilly and CompanyKyowa Kirin International plcMylan N.V.Novartis AGPfizer, Inc.SEGMENTATIONS IN REPORT:By Product Type:Creams/GelsPatchesInjectionsGums/Buccal AdhesivesImplantsOralBy Ingredient Type:TestosteroneMethyl TestosteroneTestosterone UndecanoateTestosterone EnanthateTestosterone CypionateBy Geography:North AmericaEuropeAsia PacificLatin AmericaMiddle East And AfricaDownload Free Sample Report of Global Testosterone Replacement Therapy Market @ https://www.decisiondatabases.com/contact/download-sample-8960The Global Testosterone Replacement Therapy Market has been exhibited in detail in the following chapters –Chapter 1 Testosterone Replacement Therapy Market PrefaceChapter 2 Executive SummaryChapter 3 Testosterone Replacement Therapy Industry AnalysisChapter 4 Testosterone Replacement Therapy Market Value Chain AnalysisChapter 5 Testosterone Replacement Therapy Market Analysis By Product TypeChapter 6 Testosterone Replacement Therapy Market Analysis By Ingredient TypeChapter 7 Testosterone Replacement Therapy Market Analysis By GeographyChapter 8 Competitive Landscape Of Testosterone Replacement Therapy CompaniesChapter 9 Company Profiles Of Testosterone Replacement Therapy IndustryPurchase the complete Global Testosterone Replacement Therapy Market Research Report @ https://www.decisiondatabases.com/contact/buy-now-8960Other Reports by DecisionDatabases.com:Global CAR T Cell Therapy Market Research Report – Industry Analysis, Size, Share, Growth, Trends And Forecast Till 2026Global Brachytherapy Market Research Report – Industry Analysis, Size, Share, Growth, Trends And Forecast Till 2026Global Plasma Therapy Market Research Report – Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2026About-Us:DecisionDatabases.com is a global business research reports provider, enriching decision makers and strategists with qualitative statistics.
DecisionDatabases.com is proficient in providing syndicated research report, customized research reports, company profiles and industry databases across multiple domains.Our expert research analysts have been trained to map client’s research requirements to the correct research resource leading to a distinctive edge over its competitors.
We provide intellectual, precise and meaningful data at a lightning speed.For more details:DecisionDatabases.comE-Mail: [email protected]: +91 9028057900Web: https://www.decisiondatabases.com/
Ophthalmic Pharmaceutical Drugs market is segmented by companies, region (country), by Type, and by Application.
Players, stakeholders, and other participants in the global Ophthalmic Pharmaceutical Drugs market will be able to gain the upper hand as they use the report as a powerful resource.
The segmental analysis focuses on market size and forecast for the period 2016-2027.
Download FREE Sample of this Report @ https://www.grandresearchstore.com/report-sample/global-ophthalmic-pharmaceutical-drugs-key-trends-opportunities-2027-935Segment by Type, the Ophthalmic Pharmaceutical Drugs market is segmented intoPrescription DrugsOver-the-Counter DrugsSegment by Application, the Ophthalmic Pharmaceutical Drugs market is segmented into Hospital PharmaciesDrug StoresOnline PharmaciesOthersRegional and Country-level AnalysisThe report offers exhaustive assessment of different region-wise and country-wise Ophthalmic Pharmaceutical Drugs markets such as the U.S., Canada, Germany, France, the U.K., Italy, Russia, China, Japan, South Korea, Taiwan, India, Australia, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Argentina, Saudi Arabia, UAE, Turkey, etc.The report includes country-wise and region-wise market size for the period 2016-2027, by countries (regions), by Type, and by Application, as well as by players for North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.Competitive Landscape and Ophthalmic Pharmaceutical Drugs Market Share AnalysisOphthalmic Pharmaceutical Drugs market competitive landscape provides details and data information by vendors.
The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2016-2021.
It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2016-2021.
Index Markets Research offers a detailed research on Global Women’s Health Market with the future prospects of the market to provide the current state and emerging trends in the market.
The report covers methodical outlook by considering aspects such as market growth, market demands, business strategies, consumption volume, market trends and industry cost structure during the forecast period 2018-2025.
New vendors in the market are facing tough competition from established international vendors as they struggle with technological innovations, reliability and quality issues.
The Prominent Manufacturers included Merck & Co., Inc., Eli Lilly and Company, Novartis AG, Pfizer, Inc., Novo Nordisk A/S, Bayer AG, Bayer AG, Lupin Pharmaceuticals, Inc., Sanofi, Allergan Plc, GlaxoSmithKline plc, Johnson & Johnson, AstraZeneca, F. Hoffmann-La Roche Ltd..The Women’s Health Market report includes a brief on these trends that can help the businesses operating in the industry to understand the market and strategize for their business expansion accordingly.
The research report analyzes the market size, industry share, growth, key segments, CAGR and key drivers.
In this part, the report presents the company profile, product specifications, capacity, production value, and 2013-2018 market shares for each company.
The global personalized retail nutrition and wellness market size is anticipated to reach USD 3.1 billion by 2027, according to a new report by Radiant Insights, Inc., registering a CAGR of 8.5% over the forecast period.
Increase in awareness about preventive healthcare and general well-being, trend of customization of food for a better diet, and rise in awareness about healthy food to promote nutrition and wellness are factors driving the growth of the market.
Download Free Sample Report @ https://www.radiantinsights.com/research/personalized-retail-nutrition-and-wellness-market/request-sample Start-ups such as STYR, Food Marble, and Habit Food Personalized, LLC are actively involved in the development, commercialization, and retail of nutrition and wellness solutions and offer products such as nutraceuticals, dietary supplements, and functional foods.
For instance, in February 2019, Segterra, Inc. entered into a partnership with Helix to commercialize its GoalGetter personalized model through Helix’s marketplace.
Further key findings from the report suggest: • Repeat recommendation dominated the overall market in 2019 and this trend is expected to continue through the forecast period owing to an increase in the number of pregnant women and patients with cardiovascular disorders.
These patients require monitoring on a regular basis, thereby driving the segment growth • Dietary supplements and nutraceuticals for repeat recommendation is expected to register the highest CAGR from 2020 to 2027.
